ALMS trial update: envudeucitinib shows subgroup efficacy in SLE
LUMUS Phase 2b in SLE did not meet primary endpoints overall, but robust efficacy was reported in the IFNGS-high subgroup. Envudeucitinib was described as well tolerated, with Phase 3 plans underway.
The LUMUS Phase 2b trial in SLE did not meet primary endpoints in the overall population, but robust efficacy was observed in the IFNGS-high subgroup, which represents the majority of moderate-to-severe patients.
Envudeucitinib was well tolerated, and plans are underway for Phase 3 trials focusing…